1.Non-small Cell Lung Cancer Initially Presenting with Intracardiac Metastasis.
Jung Han KIM ; Joo Young JUNG ; Young Iee PARK ; Sang Ik HWANG ; Chull Sung JUNG ; Sang Hak LEE ; Chong Woo YOO
The Korean Journal of Internal Medicine 2005;20(1):86-89
Intracardiac metastasis as the initial presentation of malignant neoplasm is very rare. We report here on a 64-year-old man with non-small cell lung cancer (NSCLC) initially presenting with intracardiac metastasis which was identified with 18-F fluorodeoxyglucose positron emission tomography (FDG PET). The patient was admitted with complaints of exertional dyspnea and vague chest discomfort that had developed a few weeks ago. Two-dimensional echocardiography revealed a heart mass attached to its akinetic wall in the right ventricular chamber. CT and MRI demonstrated a large tumor involving the epicardium and myocardium in the right ventricle, and there was a mass in the right lower lobe of the lung along with multiple lymphadenopathies. Cytologic examination of the percutaneous needle aspiration of a lymph node in the anterior mediastinum revealed malignant epithelial cell nests, and this was strongly suggestive of squamous cell carcinoma. Subsequent FDG PET confirmed that the intracardiac mass had an abnormally increased FDG uptake, and again this was strongly suggestive of malignancy. By systemically considering these imaging studies, we were able to diagnose the mass as intracardiac metastasis of NSCLC.
Carcinoma, Non-Small-Cell Lung/*diagnosis
;
Heart Neoplasms/diagnosis/*secondary
;
Heart Ventricles/pathology
;
Humans
;
Lung Neoplasms/*diagnosis
;
Male
;
Middle Aged
2.Research Progress on Risk Factors of Brain Metastasis in Non-small Cell Lung Cancer.
Shuang SUN ; Yu MEN ; Zhouguang HUI
Chinese Journal of Lung Cancer 2022;25(3):193-200
Brain metastasis of non-small cell lung cancer (NSCLC) is a common treatment failure mode, and the median survival time of NSCLC patients with brain metastasis is only 1 mon-2 mon. Prophylactic cranial irradiation (PCI) can delay the occurrence of brain metastasis, but the survival benefits of NSCLC patients are still controversial. It is particularly important to identify the patients who are most likely to benefit from PCI. This article reviews the high risk factors of brain metastasis in NSCLC.
.
Brain Neoplasms/secondary*
;
Carcinoma, Non-Small-Cell Lung/pathology*
;
Cranial Irradiation
;
Humans
;
Lung Neoplasms/pathology*
;
Risk Factors
3.Research progress of prophylactic cranial irradiation for locally advanced non-small cell lung cancer.
Yuanyuan CUI ; Hang LI ; Yu ZHANG
Chinese Journal of Oncology 2016;38(1):1-3
As multi-modality treatments are now able to ensure better local control and a lower rate of extra-cranial metastasis, brain metastasis has become a major concern in locally advanced non-small cell lung cancer (LA-NSCLC). Prophylactic cranial irradiation (PCI) is now a standard treatment for patients with small cell lung cancer (SCLC), it decreases the incidence of brain metastases and increases the survival rate. Despite the relatively high incidence of brain metastases in LA-NSCLC, the role of PCI in patients treated with radical intent has not been established yet. The objective of this systematic review was to establish whether PCI prevents the development of brain metastasis and increases survival in LA-NSCLC patients, the characteristics of the benefit patients, the tolerance and toxicity, the effective dose and timing of PCI. The main concern in this review is to establish the definitive role of PCI in the treatment of locally advanced NSCLC.
Biomedical Research
;
Brain Neoplasms
;
prevention & control
;
secondary
;
Carcinoma, Non-Small-Cell Lung
;
prevention & control
;
secondary
;
Cranial Irradiation
;
Humans
;
Lung Neoplasms
;
Small Cell Lung Carcinoma
;
prevention & control
;
secondary
;
Survival Rate
4.Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases.
Yon Ju RYU ; Eun Mi CHUN ; Soon Nam LEE ; Sung Shin SHIM
Korean Journal of Radiology 2014;15(2):300-304
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.
Antineoplastic Agents/*adverse effects
;
Brain Neoplasms/secondary
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary
;
Cysts/*chemically induced
;
Female
;
Humans
;
Lung/pathology
;
Lung Diseases/*chemically induced
;
Lung Diseases, Interstitial
;
Lung Neoplasms/*drug therapy
;
Middle Aged
;
Quinazolines/*adverse effects
5.Correlative study between expression of BRI gene and metastatic potential in human non-small cell lung cancer.
Ying-zhun CHEN ; Yu LI ; Rong ZOU ; Yu CHEN ; Yan-ying WANG ; Hui-chen FENG ; Wu-ru WANG
Chinese Journal of Pathology 2004;33(1):62-66
OBJECTIVETo investigate the potential relationship between BRI gene expression and metastatic potential in human non-small cell lung cancer (NSCLC).
METHODSUsing semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) and Northern blot hybridization techniques, differential expression of the BRI gene in human lung adenocarcinoma cell lines AGZY-83-a and Anip-973 was investigated. Having a much higher metastatic potential, Anip-973 was isolated from AGZY-83-a parental cell line. In addition, the other 6 non-small cell lung cancer cell lines (SPC-A-1, A549, 95D, TKB-18, GLC-82, PAa) and 30 samples of lung cancer tissues with matched corresponding adjacent normal tissues were also analyzed.
RESULTSThere were significant differences in BRI gene expression between the two cell lines. BRI was preferentially expressed in Anip-973 cells compared to its parental cell line AGZY-83-a, and was also up-regulated in the other 6 lung cancer cell lines, correlating possibly with their metastatic potentials. BRI gene over-expression was observed in 30 lung cancer tissues compared with its corresponding adjacent normal tissues. A relative over-expression of BRI mRNA (tumor/normal >or= 2) was observed in 6 of 8 cancer samples with lymph node metastasis and 10 of 22(45.5%) samples without lymph node metastasis. Furthermore, two mRNA transcripts of BRI gene were observed: a 2.0 kb transcript which was mainly observed in normal lung tissues and a 1.6 kb transcript which was present as a dominant species in cancer tissues.
CONCLUSIONBRI mRNA expression is significantly up-regulated in NSCLC cell lines and clinical tumor samples. An alternatively spliced 1.6 kb mRNA is a major transcript of the gene in NSCLCs, suggesting that differential RNA processing and expression of BRI gene may play a role in the tumorigenesis and/or be related to the metastatic potential of human lung cancer.
Animals ; Carcinoma, Non-Small-Cell Lung ; genetics ; secondary ; Humans ; Lung Neoplasms ; genetics ; pathology ; Mice ; Neoplasm Metastasis ; Pathology ; Reverse Transcriptase Polymerase Chain Reaction
6.Impact of micrometastasis in pathologically negative lymph node on staging and prognosis of non-small cell lung cancers.
Ruheng ZHENG ; Di GE ; Yulei QIAO ; Meixin SHI
Chinese Journal of Oncology 2002;24(1):41-43
OBJECTIVETo study the influence of micrometastasis in lymph node on staging and prognosis of non-small-cell lung cancer (NSCLC).
METHODSIn 39 NSCLC patients, micrometastasis in pathologically negative lymph nodes were tested through immunohistochemical cytokeratin (CK) analysis and the relationship between CK(+) and staging, survival were analyzed.
RESULTSIn these 39 patients, the survival of CK(+) and CK(-) patients were 32 months and 48 months respectively (P = 0.0178). Multivariate analysis of Cox regression model showed: clinical stage (P = 0.0288) and relapse or metastasis (P = 0.0053) affected the prognosis while micrometastasis in lymphnodes (P = 0.7740) did not.
CONCLUSIONThe detection of micrometastasis in the lymphnodes may serve as a supplement to the present staging system for lung cancer. Even though the prognosis of patients with micrometastasis being poorer than those without, micrometastasis in the lymph nodes should not be regarded as an independent prognostic factor.
Adult ; Aged ; Carcinoma, Non-Small-Cell Lung ; diagnosis ; metabolism ; secondary ; Female ; Humans ; Keratins ; metabolism ; Lung Neoplasms ; diagnosis ; metabolism ; pathology ; Lymph Nodes ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis
7.A Single Center, Retrospective Analysis of Prognosis in Non-small Cell Lung Cancer Patients with Peritoneal Carcinomatosis.
Baoshan CAO ; Yan'e LIU ; Wencheng YIN ; Qian LI ; Li LIANG
Chinese Journal of Lung Cancer 2019;22(3):143-150
BACKGROUND:
Peritoneal carcinomatosis is a rare clinical event in lung cancer and the prognosis is very poor. There are limited data on what factors predict peritoneal progression and affect the outcome. The aim of this study is to investigate investigate the factors associated with peritoneal carcinomatosis.
METHODS:
The patients with non-small cell lung cancer (NSCLC) from the Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital were eligible for retrospective analysis between August 2010 and August 2018. Clinical factors such as age, gender, histology, pleural effusion and gene mutations with epidermal growth factor receptor/anaplastic lymphoma kinase/ROS proto-oncogene 1 receptor tyrosine kinase (EGFR/ALK/ROS1) were analyzed. Overall survival (OS) was calculated by the Kaplan-Meier method.
RESULTS:
1.44% (12/836) patients in this study developed peritoneal carcinomatosis and 12 patients with adenocarcinoma had metachronous NSCLC diagnosis and PC. Malignant pleural effusion rates at baseline and at PC diagnosis were separately 50% (6/12) and 100.0% (12/12). Among the 12 patients, 9 patients harbored EGFR/ALK/ROS1 mutation. The outcome of patients with EGFR/ALK/ROS1 mutation was significantly better than that of patients without EGFR/ALK/ROS1 mutation, the mOS1 and mOS2 were separately 26.0 months and 6.0 months versus 10.0 months and 1.5 months (P<0.05). The mOS2 of patients with aggressive treatment after PC diagnosis was 6.0 months, significantly better than 1.0 month of patients with best supportive care (P<0.05). The mOS2 of the patients with angiogenesis inhibitors based-treatment after PC diagnosis was 8.5 months, significantly longer than that of patients with other treatments (P<0.05).
CONCLUSIONS
Adenocarcinoma and malignant pleural effusion are highly associated with peritoneal carcinomatosis in patients with advanced NSCLC. Aggressive treatment for lung cancer with PC is encouraged when possible. More patients with PC may benefit from the treatment strategies with angiogenesis inhibitors. Further prospective trials are urgently needed.
Adult
;
Aged
;
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
pathology
;
therapy
;
Female
;
Humans
;
Lung Neoplasms
;
diagnosis
;
pathology
;
therapy
;
Male
;
Middle Aged
;
Peritoneal Neoplasms
;
secondary
;
Prognosis
;
Retrospective Studies
8.Research Progress of Immunotherapy for Brain Metastases in Patients with Drive Gene Negative NSCLC.
Shuang ZHANG ; Jingjing LIU ; Changliang YANG ; Shuang LI ; Ying CHENG
Chinese Journal of Lung Cancer 2018;21(8):610-614
Brain metastasis was a common metastasis site and leading cause of death in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors had improved survival of NSCLC patients with positive drive gene. It also brings good news to NSCLC patients with positive drive gene and brain metastases. However, there is still no effective treatment for NSCLC patients with drive gene-negative and brain metastases. In recent years, immunotherapy has made breakthrough progress and become important first and second line treatment options of NSCLC especially in patients with drive gene-negative. The role of immunotherapy in specific populations of NSCLC-brain metastasis patients, especially drive gene-negative patients has become the focus of attention. In this report, we review the research progress of immunotherapy in NSCLC with brain metastases, especially in driver-negative patients, analyze the limitations of existing research and future challenge.
.
Brain Neoplasms
;
immunology
;
secondary
;
therapy
;
Carcinoma, Non-Small-Cell Lung
;
genetics
;
pathology
;
Humans
;
Immunotherapy
;
methods
;
Lung Neoplasms
;
genetics
;
pathology
;
Patient Selection
9.Investigation of Methods and Influencing Factors to Increase the Positive Rate of Cytological Pathology of Cerebrospinal Fluid from Lung Cancer Leptomeningeal Metastases.
Naisheng GAO ; Chong TENG ; Chengjuan FAN ; Tao XIN
Chinese Journal of Lung Cancer 2022;25(11):789-796
BACKGROUND:
In advanced non-small cell lung cancer (NSCLC), leptomeningeal metastases (LM) is a common consequence with rapid progression and a poor prognosis. LM affects roughly 3% to 5% of NSCLC patients, and it affects as many as 9.4% of individuals with epidermal growth factor receptor (EGFR) mutations. Cerebrospinal fluid cytology is the gold standard for diagnosing LM, while conventional cytopathology has a positive detection rate of less than 50%, resulting in a delay in diagnosis and treatment of LM. The fixation treatment of cerebrospinal fluid samples has a significant impact on the positive cytology detection rate, and how to improve the positive cytopathology detection rate of cerebrospinal fluid is a hot topic in clinical research.
METHODS:
From June 2019 to November 2021, 105 cases diagnosed with LM based on clinical symptoms and positive imaging were collected and retrospectively evaluated in the second ward of the Department of Oncology of The Second Affiliated Hospital of Harbin Medical University. The effect of different fixation methods on the positive rate of cerebrospinal fluid cytopathology was investigated, and specimens of cerebrospinal fluid were collected and sent for examination using different delivery methods, including the application of the TIB cell preservation solution kit (experimental group) and the routine application of sterile plastic tubes in lumbar puncture bags (control group). Biochemical assays (glucose and total protein) were performed on the cerebrospinal fluid fluid, and Logistic regression analysis and receiver operating characteristic (ROC) curve were used to evaluate the supplementary diagnostic value for LM patients with lung cancer. The relevance of chemical indexes in the assessment of therapeutic efficacy was examined, and biochemical (glucose, total protein) indices and cytological changes in cerebrospinal fluid fluid after pemetrexed intrathecal injection therapy were dynamically monitored.
RESULTS:
In the control group, 24 (45.28%) patients were positive for the first time, while 42 (80.77%) patients were positive for the first time and 10 (19.23%) patients were negative for the first time in the experimental group. Significant differences existed between the two groups (P<0.001). The results of Logistic regression analysis of patients with the first cerebrospinal fluid biochemical test showed that the risk of positive cerebrospinal fluid biochemical pathology with less than 2.5 mmol/L was 2.456 times greater than 2.5 mmol/L of cerebrospinal fluid glucose (OR=2.456, P<0.05), and total cerebrospinal fluid biochemical protein greater than 430 mg/L was 2.647 times less than 430 mg/L (OR=2.647, P>0.05). The ROC curve showed glucose sensitivity of 76.9% in cerebrospinal fluid, the specificity of 54.5%, Youden index of 0.315 and area under the curve (AUC) of 0.620, total protein sensitivity in cerebrospinal fluid of 44.4%, 90.6%, Youden index of 0.350 and AUC of 0.671. After 2 cycles of pemetrexed intrathecal treatment with complete cerebrospinal fluid cytology and cerebrospinal fluid biochemical (glucose, total protein) tests in 73 and 50 patients, respectively, the rate of cerebrospinal fluid cytology turning negative was gradually increased. Cerebrospinal fluid glucose levels increased after 2 cycles of treatment compared with the first time, with a statistically significant difference (P<0.001).
CONCLUSIONS
The use of a cell preservation solution kit to immediately fix cerebrospinal fluid samples following isolation in patients with clinical symptoms and positive imaging greatly enhances the rate of positive cerebrospinal fluid cytology detection. The effect of treatment can be assessed and predicted by continuous dynamic monitoring of cerebrospinal fluid biochemistry and cytology.
Humans
;
Lung Neoplasms/pathology*
;
Carcinoma, Non-Small-Cell Lung/pathology*
;
Pemetrexed/therapeutic use*
;
Retrospective Studies
;
Meningeal Carcinomatosis/secondary*
;
Glucose/therapeutic use*
10.Comparison of the Survival Time in the Non-small Cell Lung Cancer Patients with Different Organ Metastasis.
Bingqun WU ; Shenhai WEI ; Jintao TIAN ; Xiaoping SONG ; Pengcheng HU ; Yong CUI
Chinese Journal of Lung Cancer 2019;22(2):105-110
BACKGROUND:
The purpose of this study is to compare the survival time of non-small cell lung cancer (NSCLC) patients with different organ metastasis. Among all cancers, the morbidity and mortality of lung cancer is the highest worldwide, which may caused by local recurrence and distant metastasis, and the location of metastasis may predict the prognosis of patients.
METHODS:
A total of 117,542 patients with NSCLC diagnosed between 2010 and 2014 were enrolled from Surveillance, Epidemiology, and End Result (SEER) databases, and the relationship between distant metastasis and survival time was retrospectively analyzed.
RESULTS:
Of all the 117,542 patients diagnosed with non-small cell lung cancer, 42,071 (35.8%) patients had different degrees of distant metastasis during their medical history, including 26,932 single organ metastases and 15,139 multiple organ metastases, accounting for 64.0% and 36.0% of the metastatic patients respectively. Compared with patients with no metastasis, whose median survival time was 21 months, the median survival time of patients with metastases was 7 months (lung), 6 months (brain), 5 months (bone), 4 months (liver), and 3 months (multiple organ) respectively, and the difference was significant (P<0.001, except liver vs multiple organ P=0.650); Most patients with NSCLC (88.4%) eventually died of lung cancer.
CONCLUSIONS
Distant metastasis of NSCLC patients indicates poor prognosis. In NSCLC patients with single organ metastasis, the prognosis of lung metastasis is the best, and liver metastasis is the worst, and multiple organ metastasis is worse than single organ metastasis.
Aged
;
Aged, 80 and over
;
Bone Neoplasms
;
mortality
;
secondary
;
Brain Neoplasms
;
mortality
;
secondary
;
Carcinoma, Non-Small-Cell Lung
;
mortality
;
pathology
;
Female
;
Humans
;
Liver Neoplasms
;
mortality
;
secondary
;
Lung Neoplasms
;
mortality
;
pathology
;
Male
;
Middle Aged
;
Neoplasm Metastasis
;
Neoplasm Staging
;
Prognosis
;
Retrospective Studies